Advance Prostate Cancer Consensus Conference 2021: Report
Advance Prostate Cancer Consensus Conference 2021: Report
Recent advances in the treatment of patients with exon 20 insertion-positive NSCLC
Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma refractory to anti-PD-1 therapy
Safety and efficacy of olaparib plus metronomic cyclophosphamide and metformin in advanced/metastatic endometrial cancer
Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours
Safety and efficacy of the oral ATR inhibitor elimusertib in advanced solid tumours with DNA damage response defects
PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations
METNET: A phase II trial of metformin in patients with well differentiated neuroendocrine tumours
EGFR testing: Best practice for NSCLC patients with exon 20 insertions
SG in combination with pembro in patients with mUC who progressed after platinum (PLT)-based regimens
NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion
Update: Cabozantinib plus nivolumab demonstrates continued survival benefit in aRCC